News and Trends 17 Jul 2017 A Brand New Outlook on Induced Pluripotent Stem Cells In an exclusive interview with Dr David Hallett, we discover why iPS cells are the perfect replacement for human embryonic stem cells, what is so unique about them and the challenges researchers face in the field! Talk of using human stem cells to better understand and even cure diseases has been around for a few decades. […] July 17, 2017 - 8 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 3 Jul 2017 From Rockets to DNA – From SpaceX to CRISPR With CRISPR being one of the most significant discoveries in genome engineering history, many scientists are now turning towards it as a basic foundation of their research. In response, companies are developing new technologies and products designed to help these very scientists become more effective in their research. One such company is Silicon Valley entity […] July 3, 2017 - 6 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
In Depth 13 Jun 2017 Will Gene Editing Bypass the GMO Struggle or Worsen Public Distrust? In the US, the first CRISPR-edited crops were able to bypass GMO regulations, but Europe’s plant scientists are still awaiting the final go ahead. In April 2016, the US Department of Agriculture (USDA) gave the green light to the first CRISPR-edited crops, a mushroom that has been engineered to resist browning and a waxy corn from […] June 13, 2017 - 6 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 27 May 2017 “Trust me, I’m an Artist” Explores the Ethics of Biotech in Amsterdam The exhibition in Amsterdam showcases the works of ten bioartists questioning the huge complexity of ethics in the rapidly developing field of biotechnology. The Waag Society has brought together bioartists from all over Europe that explore topics like gene editing, antibiotics, human tissue culture, public health and personalized medicine. After a series of performances discussed […] May 27, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 22 Apr 2017 Art Made with CRISPR Aims to Raise Awareness of Antibiotic Resistance Anna Dumitriu’s latest bioart piece is a historic dress carrying bacteria genetically modified using CRISPR and opens the debate on antibiotic resistance. A wartime women’s suit is the canvas where Anna Dumitriu paints the history of antibiotics. The holes and stains in the suit are patched and embroidered with silk that has been dyed with E. […] April 22, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 28 Mar 2017 Europe Turns the Tables in the CRISPR Patent Battle ERS Genomics has announced that the EPO intends to grant a patent with broad claims covering the use of CRISPR to Emmanuelle Charpentier. ERS Genomics has announced that the European Patent Office (EPO) will grant its founder, Emmanuelle Charpentier as well as the University of Vienna and University of California, Berkeley, a patent covering the broad use of CRISPR-Cas9 […] March 28, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 15 Mar 2017 Allergan makes a deal with Editas to License CRISPR Programs for Eye Disease Allergan has signed a deal with Editas Medicine to access its CRISPR technology and license up to five of its programs in ocular disease. The Irish Allergan has a certain tendency to go on shopping sprees. Its latest deal is a research and development alliance with the American Editas Medicine, which is on the side of […] March 15, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 16 Feb 2017 The Patent Office has Spoken: What does it Mean for CRISPR in Europe? The US Patent Office has ruled that the Broad Institute’s CRISPR patents do not interfere with those from UC Berkeley. While this might sound like everybody wins, it’s actually a loss for Charpentier and the CRISPR Therapeutics team. CRISPR has been hailed as the ‘scientific discovery of the century’. This molecular technique could be used […] February 16, 2017 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 16 Jan 2017 The UK Steps Up its Game in Automated CRISPR Gene Editing Horizon Discovery now has full access to CRISPR technology and will develop an automated gene editing platform in collaboration with Solentim. Horizon Discovery, based in Cambridge, UK, uses gene editing technology to create custom cell lines for research. To step up its game, the company has upgraded its existing license with ERS Genomics‘ to obtain […] January 16, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 6 Jan 2017 ‘Packaged’ CRISPR Systems to Standardize novel Biomedical Research There’s a growing appetite to refine and standardize CRISPR protocols, as its application expands into different areas of genomic research. The Wellcome Trust and Desktop Genomics have recent advances to make it more efficient and controllable. Outside of the high-stakes world of therapeutic CRISPR, which has enjoyed gambling-like investment and whose legal future is unfolding in court, this […] January 6, 2017 - 3 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
Best in Biotech 3 Jan 2017 10 Hot European Biotechs to Observe in 2017 🚀 New year, new list: here are the 10 hottest Biotech companies I will watch closely in 2017 and why. This list is not meant to be comprehensive and is in no particular order. Super-pumped mRNA Therapy BioNTech is Europe’s largest private Biotech with over 500 employees and is one of the three leading mRNA therapy […] January 3, 2017 - 5 minutesmins - By Philip Hemme Share WhatsApp Twitter Linkedin Email
News and Trends 26 Dec 2016 The Largest Deals, Fundraising and Exits of 2016 in European Biotech Curious about which technologies have attracted the most cash in biotech finance this year? Here’s a list of the most impressive cash movements of 2016 in Europe. Believe it or not, 2016 has been the worst year for biotech finance in a decade. The political scene has become unfavorable for British biotech after Brexit, and the uncertainty raised by […] December 26, 2016 - 5 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email